Cargando…

Update of P2X receptor properties and their pharmacology: IUPHAR Review 30

The known seven mammalian receptor subunits (P2X1–7) form cationic channels gated by ATP. Three subunits compose a receptor channel. Each subunit is a polypeptide consisting of two transmembrane regions (TM1 and TM2), intracellular N- and C-termini, and a bulky extracellular loop. Crystallization al...

Descripción completa

Detalles Bibliográficos
Autores principales: Illes, Peter, Müller, Christa E., Jacobson, Kenneth A., Grutter, Thomas, Nicke, Annette, Fountain, Samuel J., Kennedy, Charles, Schmalzing, Günther, Jarvis, Michael F., Stojilkovic, Stanko S., King, Brian F., Virgilio, Francesco Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199792/
https://www.ncbi.nlm.nih.gov/pubmed/33125712
http://dx.doi.org/10.1111/bph.15299
_version_ 1783707460956061696
author Illes, Peter
Müller, Christa E.
Jacobson, Kenneth A.
Grutter, Thomas
Nicke, Annette
Fountain, Samuel J.
Kennedy, Charles
Schmalzing, Günther
Jarvis, Michael F.
Stojilkovic, Stanko S.
King, Brian F.
Virgilio, Francesco Di
author_facet Illes, Peter
Müller, Christa E.
Jacobson, Kenneth A.
Grutter, Thomas
Nicke, Annette
Fountain, Samuel J.
Kennedy, Charles
Schmalzing, Günther
Jarvis, Michael F.
Stojilkovic, Stanko S.
King, Brian F.
Virgilio, Francesco Di
author_sort Illes, Peter
collection PubMed
description The known seven mammalian receptor subunits (P2X1–7) form cationic channels gated by ATP. Three subunits compose a receptor channel. Each subunit is a polypeptide consisting of two transmembrane regions (TM1 and TM2), intracellular N- and C-termini, and a bulky extracellular loop. Crystallization allowed the identification of the 3D structure and gating cycle of P2X receptors. The agonist-binding pocket is located at the intersection of two neighbouring subunits. In addition to the mammalian P2X receptors, their primitive ligand-gated counterparts with little structural similarity have also been cloned. Selective agonists for P2X receptor subtypes are not available, but medicinal chemistry supplied a range of subtype-selective antagonists, as well as positive and negative allosteric modulators. Knockout mice and selective antagonists helped to identify pathological functions due to defective P2X receptors, such as male infertility (P2X1), hearing loss (P2X2), pain/cough (P2X3), neuropathic pain (P2X4), inflammatory bone loss (P2X5), and faulty immune reactions (P2X7).
format Online
Article
Text
id pubmed-8199792
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-81997922022-02-01 Update of P2X receptor properties and their pharmacology: IUPHAR Review 30 Illes, Peter Müller, Christa E. Jacobson, Kenneth A. Grutter, Thomas Nicke, Annette Fountain, Samuel J. Kennedy, Charles Schmalzing, Günther Jarvis, Michael F. Stojilkovic, Stanko S. King, Brian F. Virgilio, Francesco Di Br J Pharmacol Article The known seven mammalian receptor subunits (P2X1–7) form cationic channels gated by ATP. Three subunits compose a receptor channel. Each subunit is a polypeptide consisting of two transmembrane regions (TM1 and TM2), intracellular N- and C-termini, and a bulky extracellular loop. Crystallization allowed the identification of the 3D structure and gating cycle of P2X receptors. The agonist-binding pocket is located at the intersection of two neighbouring subunits. In addition to the mammalian P2X receptors, their primitive ligand-gated counterparts with little structural similarity have also been cloned. Selective agonists for P2X receptor subtypes are not available, but medicinal chemistry supplied a range of subtype-selective antagonists, as well as positive and negative allosteric modulators. Knockout mice and selective antagonists helped to identify pathological functions due to defective P2X receptors, such as male infertility (P2X1), hearing loss (P2X2), pain/cough (P2X3), neuropathic pain (P2X4), inflammatory bone loss (P2X5), and faulty immune reactions (P2X7). 2020-12-21 2021-02 /pmc/articles/PMC8199792/ /pubmed/33125712 http://dx.doi.org/10.1111/bph.15299 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Illes, Peter
Müller, Christa E.
Jacobson, Kenneth A.
Grutter, Thomas
Nicke, Annette
Fountain, Samuel J.
Kennedy, Charles
Schmalzing, Günther
Jarvis, Michael F.
Stojilkovic, Stanko S.
King, Brian F.
Virgilio, Francesco Di
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title_full Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title_fullStr Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title_full_unstemmed Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title_short Update of P2X receptor properties and their pharmacology: IUPHAR Review 30
title_sort update of p2x receptor properties and their pharmacology: iuphar review 30
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199792/
https://www.ncbi.nlm.nih.gov/pubmed/33125712
http://dx.doi.org/10.1111/bph.15299
work_keys_str_mv AT illespeter updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT mullerchristae updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT jacobsonkennetha updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT grutterthomas updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT nickeannette updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT fountainsamuelj updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT kennedycharles updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT schmalzinggunther updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT jarvismichaelf updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT stojilkovicstankos updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT kingbrianf updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30
AT virgiliofrancescodi updateofp2xreceptorpropertiesandtheirpharmacologyiupharreview30